https://www.selleckchem.com/products/k03861.html
We also extracted data on treatment-related adverse events and immune-related adverse events (irAEs). Overall, 10 randomised controlled clinical trials (n=5765) were included. As first-line treatment for advanced NSCLC, IC tended to yield better PFS, OS and ORR than did IO. Furthermore, IC yielded significantly better PFS than IO when tumour PD-L1 expression was at least 50% (HR 1.81, 95% CI 1.18 to 2.78) and yielded a better OS and PFS when tumour PD-L1 expression was at least 1%; IO resulted in fewer adverse events than did IC. However
Like
Comment
Share
